Data are currently lacking demonstrating whether current GH dosing regimens promote any tumor recurrence or re-growth (Frajese et al., 2001; Hatrick et al., 2002; Chung et al., 2005, 2008; Jostel et al., 2005; Karavitaki et al., 2006; Buchfelder et al., 2007; Arnold et al., 2009; Olsson et al., 2009). This evidence concerns the gene GH1 and neoplasm.